Anixa Biosciences and OntoChem Identify First COVID-19 Therapeutic Candidate

Anixa Biosciences and OntoChem have identified their first potential COVID-19 therapeutic agent and have advanced it to testing.

The drug is designed to disrupt the interaction of the virus's endoribonuclease with a protein that is necessary for the virus to replicate in the body.

Anixa believes that drugs specifically targeting SARS-CoV-2 will prove to be more effective than repurposed medicines for other diseases.